Applications of the endogenous thrombin potential;Anwendungen des endogenen Thrombinpotenzials

Hamostaseologie

Volumn 31, Issue 2, 2011, Pages 88-93

  Wilkens, M ^a  

^a Siemens Healthcare Diagnostics Products GmbH   (Germany)

Author keywords

Anticoagulation; Endogenous thrombin potential; ETP; Haemophilia; Thrombin generation; Thrombophilia

Indexed keywords

PROTHROMBIN; THROMBIN; ANTICOAGULANT AGENT;

BLEEDING; HUMAN; PLASMA; PROTHROMBIN TIME; REVIEW; THROMBOSIS; BLOOD; BLOOD CLOTTING TEST; HEMOPHILIA A; HEMOSTASIS; INTERNATIONAL NORMALIZED RATIO; METABOLISM; METHODOLOGY; PHYSIOLOGY; SENSITIVITY AND SPECIFICITY; THROMBIN TIME; THROMBOPHILIA;

ANTICOAGULANTS; BLOOD COAGULATION TESTS; HEMOPHILIA A; HEMOSTASIS; HUMANS; INTERNATIONAL NORMALIZED RATIO; PROTHROMBIN TIME; SENSITIVITY AND SPECIFICITY; THROMBIN; THROMBIN TIME; THROMBOPHILIA;

EID: 80051923146     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/ha-1130     Document Type: Review

References (44)

1. Dieri R, Peyvandi F, Santagostino E et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 2002; 88: 576-582.
2. Dieri R, Alban S, Béguin S, Hemker HC. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2004; 2: 1395-1401.
3. Dieri R, Alban S, Béguin S, Hemker HC. Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost 2006; 4: 83-89.
4. Beltrán-Miranda CP, Khan A et al. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005; 11: 326-334.
5. Bertina RM, Koeleman BP, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369(6475): 64-67.
6. Besser M, Baglin C, Luddington R et al. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost 2008; 6: 1720-1725.
7. Brocal I, Marco P, Lucas J et al. Thrombin generation test in patients under anticoagulant therapy with vitamin K antagonists. Thromb Haemost 2009; 101: 594-595.
8. Butenas S, van't Veer C, Mann KG. "Normal" thrombin generation. Blood 1999; 94: 2169-2178.
9. Chantarangkul V, Clerici M, Bressi C, Tripodi A. Standardization of the endogenous thrombin potential measurement: how to minimize the effect of residual platelets in stored plasma. Br J Haematol 2004; 124: 355-357.
10. Cumming AM, Tait RC, Fildes S et al. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995; 90: 725-727.
11. Curvers J, Thomassen MC, Rimmer J et al. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost 2002; 88: 5-11.
12. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
13. Dargaud Y, Béguin S, Lienhart A et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: 475-480.
14. Dargaud Y, Luddington R, Gray E et al. Standardisation of thrombin generation test--which reference plasma for TGT? An international multicentre study. Thromb Res 2010; 125: 353-356.
15. Duchemin J, Pittet JL, Tartary M et al. A new assay based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma. Thromb Haemost 1994; 71: 331-338.
16. Eichinger S, Hron G, Kollars M, Kyrle PA. Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clin Chem 2008; 54: 2042-2048.
17. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-4746.
18. Gerotziafas GT, Elalamy I, Depasse F et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007; 5: 886-888.
19. Gerotziafas GT, Petropoulou AD, Verdy E et al. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007; 5: 955-962, 1343.
20. Hemker HC, Willems GM, Béguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986; 56: 9-17.
21. Hemker HC, Wielders S, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-624.
22. Hemker HC, Giesen PL, Ramjee M et al. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000; 83: 589-591.
23. Jackson CM, Esnouf MP, Lindahl TL. A critical evaluation of the prothrombin time for monitoring oral anticoagulant therapy. Pathophysiol Haemost Thromb 2003; 33: 43-51.
24. Kyrle PA, Mannhalter C, Béguin S et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998; 18: 1287-1291.
25. Lecompte T, Wahl D, Perret-Guillaume C et al. Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk. Haematologica 2007; 92: 714-715.
26. Livnat T, Martinowitz U, Zivelin A, Seligsohn U. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma. Haemophilia 2008; 14: 782-786.
27. MACFARLANE RG, Biggs R. A thrombin generation test; the application in haemophilia and thrombocytopenia. J Clin Pathol 1953; 6: 3-8.
28. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003; 1: 1504-1514.
29. Olivieri O, Friso S, Manzato F et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 91: 465-470.
30. Pitney WR, Dacie JV. A simple method of studying the generation of thrombin in recalcified plasma; application in the investigation of haemophilia. J Clin Pathol 1953; 6: 9-14.
31. Regnault V, Béguin S, Lecompte T. Calibrated automated thrombin generation in frozen-thawed platelet-rich plasma to detect hypercoagulability. Pathophysiol Haemost Thromb 2003; 33: 23-29.
32. Rosendaal FR. Risk factors for venous thrombosis: prevalence, risk, and interaction. Semin Hematol 1997; 34: 171-187.
33. Samama MM, Le Flem L, Guinet C et al. Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants. Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants. J Thromb Haemost 2007; 5: 2554-2556.
34. Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemost 1997; 78: 297-301.
35. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-1231.
36. Siegemund A, Petros S, Siegemund T et al. The endogenous thrombin potential and high levels of coagulation factor VIII, factor IX and factor XI. Blood Coagul Fibrinolysis 2004; 15: 241-244.
37. Stief TW. Inhibition of thrombin generation in recalcified plasma. Blood Coagul Fibrinolysis 2007; 18: 751-760.
38. Tanaka KA, Szlam F, Katori N et al. The effects of argatroban on thrombin generation and hemostatic activation in vitro. Anesth Analg 2004; 99: 1283-1289.
39. Thomassen MCLGD, Curvers J, Rimmer JE et al. Influence of hormone replacement therapy, oral contraceptive and pregnancy on APC resistance. Thromb Haemost1999 (Suppl) 82: 770-771.
40. Van Hylckama Vlieg A, Christiansen SC, Luddington R et al. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol 2007; 138: 769-774.
41. Van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 2008; 142: 889-903.
42. Váradi K, Negrier C, Berntorp E et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374-2380.
43. Walsh PN, Rainsford SG, Biggs R. Platelet coagulant activities and clinical severity in haemophilia. Thromb Diath Haemorrh 1973; 29: 722-729.
44. Wielders S, Mukherjee M, Michiels J et al. The routine determination of the endogenous thrombin potential, first results in different forms of hyperand hypocoagulability. Thromb Haemost 1997; 77: 629-936.